Jan Joseph Melenhorst, PhD

faculty photo
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
Education:
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, Netherlands, 1988.
MS (Medical Biology)
Nijmegen Katholic University, Netherlands, 1991.
PhD (Immunology)
Leiden University, Netherlands, 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

Stadtmauer EA, Cohen AD, Weber K, Lacey SF, Gonzalez VE, Melenhorst JJ, Fraietta JA, Plesa G, Shea J, Matlawski T, Cervini A, Mangan P, Gaymon A, Desjardins S, Lancaster E, Salas-Mckee J, Suhoski MM, Fesnak A, O'Rourke M, Lamontagne A, Siegel DL, Young RM, Chew A, Nobles CL, Bushman FD, Chang HY, Satpathy AT, Zhao Y, Hwang WT, Hexner EO, June CH.: First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood 134(Supplement_1): 49, Nov 2019 Notes: doi: 10.1182/blood-2019-122374.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S.: A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood Page: pii: blood.2019001859, Nov 2019 Notes: doi: 10.1182/blood.2019001859. [Epub ahead of print]

Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR.: CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv 3(22): 3539-3549, Nov 2019 Notes: doi: 10.1182/bloodadvances.2019000692.

Alfred L. Garfall, Ehren Dancy, Adam D. Cohen, Wei-Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, and J. Joseph Melenhorst: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Advances 3(19): 2812, Oct 2019.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ*, Beatty GL*. * co-senior authors: Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cell Mol Gastroenterol Hepatol Page: pii: S2352-345X(19)30096-7, Aug 2019 Notes: doi: 10.1016/j.jcmgh.2019.07.008. [Epub ahead of print]

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL: Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther Page: pii: S1525-0016(19)30328-4, July 2019 Notes: doi: 10.1016/j.ymthe.2019.07.015. [Epub ahead of print]

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW: Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. Blood Page: pii: blood.2018885863, May 2019 Notes: doi: 10.1182/blood.2018885863. Epub ahead of print. No volume or issue at this time.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation 130(6): 2210-2221, Mar 2019 Notes: doi: 10.1172/JCI126397.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4(4): pii: 127684, Feb 2019.

Chen F, Fraietta JA, June CH, Xu Z, Melenhorst JJ, Lacey SF: Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering 5(1): 140-149, Feb 2019.

back to top
Last updated: 11/25/2019
The Trustees of the University of Pennsylvania